The effectiveness of carbamazepine in unipolar depression: A double-blind, randomized, placebo-controlled study

Journal of Affective Disorders

Volumn 109, Issue 1-2, 2008, Pages 91-97

  Zhang, Zhang Jin ^a,b   Tan, Qing Rong ^a   Tong, Yao ^b   Li, Qiang ^c   Kang, Wan Hu ^c   Zhen, Xue Chu ^d   Post, Robert M ^e  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

^c MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^d SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^e PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Carbamazepine; Clinical trial; Major depressive disorder; Unipolar depression

Indexed keywords

CARBAMAZEPINE; PLACEBO;

ADULT; AGED; ARTICLE; BLURRED VISION; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; EVALUATION; FEMALE; HAMILTON SCALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; TREMOR;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CARBAMAZEPINE; DEPRESSIVE DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 43949145968     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2007.11.004     Document Type: Article

References (40)

1. Ali S., and Milev R. Switch to mania upon discontinuation of antidepressants in patients with mood disorders: a review of the literature. Can. J. Psychiatry 48 (2003) 258-264
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (1994), American Psychiatric Association Press, Washington, DC
3. Aoki M., Tsuji M., Takeda H., Harada Y., Nohara J., Matsumiya T., and Chiba H. Antidepressants enhance the antinociceptive effects of carbamazepine in the acetic acid-induced writhing test in mice. Eur. J. Pharmacol. 550 1-3 (2006) 78-83 Nov 21
4. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 31 (1996) 444-469
5. Borowicz K.K., Stepien K., and Czuczwar S.J. Fluoxetine enhances the anticonvulsant effects of conventional antiepileptic drugs in maximal electroshock seizures in mice. Pharmacol. Rep. 58 (2006) 83-90
6. Ciusani E., Zullino D.F., Eap C.B., Brawand-Amey M., Brocard M., and Baumann P. Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. J. Psychopharmacol. 18 (2004) 559-566
7. Dietrich D.E., and Emrich H.M. The use of anticonvulsants to augment antidepressant medication. J. Clin. Psychiatry 59 S5 (1998) 51-58
8. Ginsberg L.D. Carbamazepine extended-release capsules use in bipolar disorder: efficacy and safety in adult patients. Ann. Clin. Psychiatry 18 S1 (2006) 9-14
9. Ginsberg L.D. Carbamazepine extended-release capsules: a retrospective review of its use in children and adolescents. Ann. Clin. Psychiatry 18 S1 (2006) 3-7
10. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised Bethesda (1976), US Department of Health, Education, and Welfare, MD
11. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960) 56-62
12. Hammad T.A., Laughren T., and Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch. Gen. Psychiatry 63 (2006) 332-339
13. Hamrin V., and Scahill L. Selective serotonin reuptake inhibitors for children and adolescents with major depression: current controversies and recommendations. Issues Ment. Health Nurs. 26 (2005) 433-450
14. Jarema M. Atypical antipsychotics in the treatment of mood disorders. Curr. Opin. Psychiatry 20 (2007) 23-29
15. Ketter T.A., Kalali A.H., Weisler R.H., and SPD417 Study Group. A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J. Clin. Psychiatry 65 (2004) 668-673
16. Kowatch R.A., Sethuraman G., Hume J.H., Kromelis M., and Weinberg W.A. Combination pharmacotherapy in children and adolescents with bipolar disorder. Biol. Psychiatry 53 (2003) 978-984
17. Kwamie Y., Persad E., and Stancer H. The use of carbamazepine as an adjunctive medication in the treatment of affective disorders: a clinical report. Can. J. Psychiatry 29 (1984) 605-608
18. Lee S., Tsang A., Zhang M.Y., Huang Y.Q., He Y.L., Liu Z.R., Shen Y.C., and Kessler R.C. Lifetime prevalence and inter-cohort variation in DSM-IV disorders in metropolitan China. Psychol. Med. 37 (2007) 61-71
19. Leverich G.S., Altshuler L.L., Frye M.A., Suppes T., McElroy S.L., Keck Jr. P.E., Kupka R.W., Denicoff K.D., Nolen W.A., Grunze H., Martinez M.I., and Post R.M. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am. J. Psychiatry 163 (2006) 232-239
20. Montgomery S.A. Why do we need new and better antidepressants? 1. Int. Clin. Psychopharmacol. 21 (2006) S1-S10
21. Montgomery S.A., and Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134 (1979) 382-389
22. Ng F., Dodd S., and Berk M. Combination pharmacotherapy in unipolar depression. Expert Rev. Neurother. 6 (2006) 1049-1060
23. *D (sequenced treatment alternatives to relieve depression) study. J. Psychiatr. Res. 41 (2007) 214-221
24. Post R.M. Mood disorders: treatment of bipolar disorders. In: Sadock B., and Sadock V. (Eds). Comprehensive textbook of Psychiatry. 7th ed. (2000), Lippincott Williams & Wilkins, Baltimore, MD 1385-1480
25. Post R.M. Do the epilepsies, pain syndromes, and affective disorders share common kindling-like mechanisms?. Epilepsy Res. 50 (2002) 203-219
26. Post R.M., Uhde T.W., Roy-Byrne P.P., and Joffe R.T. Antidepressant effects of carbamazepine. Am. J. Psychiatry 143 (1986) 29-34
27. Post R.M., Altshuler L.L., Leverich G.S., Frye M.A., Nolen W.A., Kupka R.W., Suppes T., McElroy S., Keck P.E., Denicoff K.D., Grunze H., Walden J., Kitchen C.M., and Mintz J. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br. J. Psychiatry 189 (2006) 124-131
28. Post R.M., Ketter T.A., Uhde T., and Ballenger J.C. Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. CNS Drugs 21 (2007) 47-71
29. Rogawski M.A., and Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat. Med. 10 (2004) 685-692
30. *D report. Am. J. Psychiatry 163 (2006) 1905-1917
31. Sachs G.S., Nierenberg A.A., Calabrese J.R., Marangell L.B., Wisniewski S.R., Gyulai L., Friedman E.S., Bowden C.L., Fossey M.D., Ostacher M.J., Ketter T.A., Patel J., Hauser P., Rapport D., Martinez J.M., Allen M.H., Miklowitz D.J., Otto M.W., Dennehy E.B., and Thase M.E. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N. Engl. J. Med. 356 (2007) 1711-1722
32. Shelton R.C. Mood-stabilizing drugs in depression. J. Clin. Psychiatry 60 S5 (1999) 37-40
33. Sitsen J., Maris F., and Timmer C. Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects. Eur. J. Drug Metab. Pharmacokinet. 26 (2001) 109-121
34. Steinacher L., Vandel P., Zullino D.F., Eap C.B., Brawand-Amey M., and Baumann P. Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. Eur. Neuropsychopharmacol. 12 (2002) 255-260
35. Stuppaeck C.H., Barnas C., Schwitzer J., and Fleischhacker W.W. Carbamazepine in the prophylaxis of major depression: a 5-year follow-up. J. Clin. Psychiatry 55 (1994) 146-150
36. Szymura-Oleksiak J., Wyska E., and Wasieczko A. Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. Psychopharmacology (Berl) 154 (2001) 38-42
37. Weisler R.H., Cutler A.J., Ballenger J.C., Post R.M., and Ketter T.A. The use of antiepileptic drugs in bipolar disorders: a review based on evidence from controlled trials. CNS Spectr. 11 (2006) 788-799
38. Williams D.R., Gonzalez H.M., Neighbors H., Nesse R., Abelson J.M., Sweetman J., and Jackson J.S. Prevalence and distribution of major depressive disorder in African Americans, Caribbean blacks, and non-Hispanic whites: results from the national survey of American life. Arch. Gen. Psychiatry 64 (2007) 305-315
39. Zhang Z.J., Kang W.H., Li Q., and Tan Q.R. The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) for mood disorders: double-blind, placebo-controlled studies. J. Psychiatr. Res. 41 (2007) 828-836
40. Zhang Z.J., Kang W.H., Tan Q.R., Li Q., Gao C.G., Zhang F.G., Wang H.H., Ma X.C., Chen C., Wang W., Guo L., Zhang Y.H., Yang X.B., and Yang G.D. Adjunctive herbal medicine with carbamazepine for bipolar disorders: a double-blind, randomized, placebo-controlled study. J. Psychiatr. Res. 41 (2007) 360-369